Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Terminated 3Withdrawn 1Unknown 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Ovarian Neoplasms 9Neoplasms 3Endometrial Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Thrombocytopenia 1Stomach Neoplasms 1Solid Tumor, Adult 1Recurrence 1Rectal Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neutropenia 1Neuroblastoma 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Glioma 1Glioblastoma 1Fallopian Tube Neoplasms 1Cystadenocarcinoma, Serous 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Biliary Tract Neoplasms 1Astrocytoma 1

Interventions

pembrolizumab 8Paclitaxel 8Carboplatin 6niraparib 3Megestrol Acetate 3Cisplatin 3tislelizumab 2technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 2rucaparib 2olaparib 2iso-sulfan blue 2copanlisib 2Taxes 2Surveys and Questionnaires 2Nivolumab 2Lymph Node Excision 2Indocyanine Green 2Fulvestrant 2Filgrastim 2Doxorubicin 2Docetaxel 2tremelimumab 1spartalizumab 1sonidegib 1ribociclib 1rebastinib 1pemigatinib 1nicotinamide-beta-riboside 1lenvatinib 1ixabepilone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Endometrial Neoplasms × niraparib × Clear all
NCT05169437 2025-10-29

PAVO

Tempus AI

Phase 2 Terminated
22 enrolled 17 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Urologic Neoplasms, Endometrial Neoplasms

NCT04159155 2025-08-12

CAN-STAMP

University Health Network, Toronto

Phase 2/3 Terminated
11 enrolled
Gynecologic

Endometrial Neoplasms, Cystadenocarcinoma, Serous

NCT05523440 2025-03-28

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

University of Oklahoma

Phase 2 Terminated
7 enrolled
Gynecologic

Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡